Over the last decade, the treatment of advanced melanoma has been significantly changed with the development of targeted and immunotherapy. Now, there is finally five-year survival data for both kinds of treatments. How do these results impact daily clinical practice?
On January 21st from 20:30 until 21:30 MEDtalks broadcasts a unique e-learning, live from a studio in Brussels, wherein an expert panel led by prof. dr. Bart Neyns will discuss first- and second-line treatment of advanced melanoma with immuno and targeted therapy in patients with or without poor prognostic factors. Furthermore, the burning question on everybody’s mind after the presentation of the five-year survival results of the CheckMate 067 trial will of course not be left untouched: should patients be treated with combination immunotherapy or monotherapy?
This programme will be available as an on-demand e-learning shortly afterwards. If you watch this live broadcast, you will be in the unique position to ask questions to the experts.
Subjects (among others)
For this e-learning, accreditation will be arranged for medical oncologists in both Belgium and the Netherlands.
Primary: Medical oncologists
Secondary: Radiotherapists, dermatologists, neurosurgeons and pathologists
University Hospital Brussels
Ghent University Hospital
GZA Hospital Sint-Augustinus
Institut Jules Bordet